Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 5/20 | 0.58 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7126423 | 0.98 | GNAO1 (0.57) | GNAO1CXCR4HRH3GNAI3GNAI1 | |
| SCHEMBL7129884 | 0.96 | GNAO1 (0.58) | GNAO1CXCR4HRH3GNAI3GNAI1 | |
| SCHEMBL5848080 | 0.94 | GNAO1 (0.56) | GNAO1CXCR4HRH3GNAI3GNAI1 | |
| SCHEMBL7122133 | 0.92 | GNAO1 (0.54) | GNAO1CXCR4HRH3GNAI3GNAI1 | |
| SCHEMBL9824369 | 0.92 | GNAO1 (0.54) | GNAO1CXCR4HRH3GNAI3GNAI1 | |
| SCHEMBL7128349 | 0.90 | GNAO1 (0.56) | GNAO1CXCR4HRH3GNAI3GNAI1 | |
| SCHEMBL30015160 | 0.90 | GNAO1 (0.60) | GNAO1CXCR4HRH3GNAI3GNAI1 | |
| SCHEMBL4157945 | 0.89 | GNAO1 (0.47) | GNAO1CXCR4HRH3GNAI3GNAI1 | |
| SCHEMBL640737 | 0.86 | GNAO1 (0.50) | GNAO1CXCR4HRH3GNAI3GNAI1 | |
| SCHEMBL42348 | 0.84 | GNAO1 (0.49) | GNAO1CXCR4HRH3GNAI3GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313726-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| EP-1311500-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-21 | — | — | EP | disclosed |
| EP-1309587-A1 | CINNOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016348-A1 | ANTIANGIOGENIC BICYCLIC DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002012228-A1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012227-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| EP-0345629-B1 | CONDENSED DIAZEPINONES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1992-09-16 | — | — | EP | disclosed |
| US-4931436-A | BRADYCARDIAL AGENTS | DR. KARL THOMAE GMBH (DE) | 1990-06-05 | — | — | US | disclosed |
| EP-0345629-A2 | Condensed diazepinones, process for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1989-12-13 | — | — | EP | disclosed |